SEC Tracker
Get the app

Prime Medicine PRME

Prime Medicine Q3 FY23: revenue $0; diluted EPS −$0.55

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Prime Medicine reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0No year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$50.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.55No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$44.0MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$39.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Prime Medicine files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  2. Annexon ANNX public float $244M, Jun 30, 2025
  3. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  4. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  5. DBV Technologies DBVT public float $251M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.